Cargando…
Successive Osteosarcoma Relapses after the First Line O2006/Sarcome-09 Trial: What Can We Learn for Further Phase-II Trials?
SIMPLE SUMMARY: Osteosarcoma is the most common primary malignant bone tumour in adolescents and young adults. The survival of osteosarcoma patients has not improved for four decades. The purpose was to describe first and subsequent relapses in patients from the OS2006/Sarcome-09 trial, to help futu...
Autores principales: | Thebault, Eric, Piperno-Neumann, Sophie, Tran, Diep, Pacquement, Hélène, Marec-Berard, Perrine, Lervat, Cyril, Castex, Marie-Pierre, Cleirec, Morgane, Bompas, Emmanuelle, Vannier, Jean-Pierre, Plantaz, Dominique, Saumet, Laure, Verite, Cecile, Collard, Olivier, Pluchart, Claire, Briandet, Claire, Monard, Laure, Brugieres, Laurence, Le Deley, Marie-Cécile, Gaspar, Nathalie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8038261/ https://www.ncbi.nlm.nih.gov/pubmed/33918346 http://dx.doi.org/10.3390/cancers13071683 |
Ejemplares similares
-
Late toxicity comparison of alkylating‐based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro‐EWING99‐R1 in France
por: Corvest, Victoria, et al.
Publicado: (2022) -
Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC’S (Observatoire de l’Utilisation des Thérapies Ciblées dans les Sarcomes)
por: Penel-Page, Mathilde, et al.
Publicado: (2015) -
Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study
por: Tabone, Marie-Dominique, et al.
Publicado: (2017) -
Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma
por: Brard, Caroline, et al.
Publicado: (2019) -
High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group
por: Marec-Berard, Perrine, et al.
Publicado: (2014)